PYC Therapeutics shares rise ahead of key kidney disease drug data readout
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Shares of PYC Therapeutics rose more than 5% on Tuesday, closing at 2.68 Australian dollars on the Australian Securities Exchange. This gain increased the company's market value to about 2.6 billion Australian dollars. The stock movement occurred as investors positioned themselves ahead of a key data readout for the company's experimental treatment for an inherited kidney disease.
From ibtimes.com.au
Why it matters
The stock advance occurred while health care stocks broadly gained 0.63%. Investor interest is focused on PYC-003, a drug candidate designed to address the underlying genetic cause of autosomal dominant polycystic kidney disease.
From ibtimes.com.au
Who's involved
- Australian Securities ExchangeOperates Australia's primary securities exchange where the shares were traded
Keep exploring
The entities involved
-
Australian Securities Exchange
public company that operates Australia's primary securities exchange
Related events
- Pan African Resources has listed its shares on the ASX for trading, while facing global supply chain pressures and increasing production at the Tennant Creek mine.
- Shares of Commonwealth Bank traded on the Australian Securities Exchange on August 31, 2026.
- Jamie Hannah commented on the ASX's struggles, noting that Nvidia backed a collapsed Firmus IPO.
- Downer EDI stock was listed on the Australian Securities Exchange on August 30, 2026.
- Ingenia Communities Group and AvalonBay Communities are competing in the residential real estate market following Ingenia's listing on the ASX.